Presentation is loading. Please wait.

Presentation is loading. Please wait.

ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide.

Published byRiitta Auvinen Modified over 5 years ago

Similar presentations

Presentation on theme: "ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide."— Presentation transcript:

1 ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide therapy.37 ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CV, cardiovascular; RRR, relative risk reduct... ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide therapy.37 ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CV, cardiovascular; RRR, relative risk reduction. Hassan Fares et al. Open Heart 2016;3:e000473 ©2016 by British Cardiovascular Society

Download ppt "ASCOT: randomised trial showing a decrease in cardiovascular mortality in patients treated with amlodipine/perindopril compared with atenolol/thiazide."

Similar presentations

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.

VBWG IDEAL: The Incremental Decrease in End Points Through Aggressive Lipid Lowering Study.
Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?

Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?
Central blood pressure: what do we really know today?

Central blood pressure: what do we really know today?
LEADER trial: Primary Outcome

LEADER trial: Primary Outcome
The Anglo Scandinavian Cardiac Outcomes Trial

The Anglo Scandinavian Cardiac Outcomes Trial
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Relative risk of major events with atenolol vs placebo

Relative risk of major events with atenolol vs placebo
Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.

Distribution of lifespan for men initiating preventative therapy (with a risk reduction of 30%) at the age of 50, with national average blood pressure.
Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.

Impact of risk factors and age of initiation of therapy on the distribution of lifespan gain. ‘National average risk’ refers to a cohort beginning at age.
Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.

Risk of perioperative renal dysfunction with N-acetylcysteine or placebo in patients undergoing CABG surgery End point N-acetylcysteine Placebo Relative.
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?

β-Blockers in Heart Failure: Breaking Tradition to Avoid Diabetes?
Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.

Any and definite stent thrombosis (ST) and in-device late lumen loss (LLL) with bioresorbable vascular scaffold (BVS) versus drug-eluting stent (DES) in.
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.

Endothelial function at baseline and follow-up (responders in white bars and non-responders in black). Endothelial function at baseline and follow-up (responders.
Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.

Risk of mortality and fatal and nonfatal cardiovascular events in highest vs lowest quartiles for troponin T End point Relative risk 95% CI p Mortality.
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Similar presentations

Ads by Google